

CURRICULUM VITAE

Name: Philip Marshall Farrell
 Date of Birth: November 26, 1943
 Place of Birth: St. Louis, Missouri

EDUCATION:

1960-1970 St. Louis University
 St. Louis, Missouri

<u>Degree</u>	<u>Major</u>	<u>Minor</u>
A.B. (1967)	Chemistry	Biology
M.D. (1970)	Medicine	
Ph.D. (1970)	Biochemistry	Physiology

Major Professor/Advisor: Robert E. Olson, M.D., Ph.D.
 Thesis: Properties of Creatine Kinase in Hereditary Muscular Dystrophy and Vitamin E Deficiency of the Chicken

POSTGRADUATE EDUCATION:

1970-1971 Internship, Department of Pediatrics
 University of Wisconsin Hospitals; Madison, Wisconsin

1971-1972 Residency, Department of Pediatrics
 University of Wisconsin Hospitals; Madison, Wisconsin

1972-1974 Fellowship, Pediatric Metabolism Branch, NIAMDD
 National Institutes of Health, Bethesda, Maryland
 (Clinical Associate of Paul A. di Sant'Agnese, M.D.)

CONTINUING EDUCATION:

1985 Fellowship in Developmental Biology; College de France

1991 "Introduction to Clinical Epidemiology" Course
 University of Michigan, School of Public Health

1992 "Program for Chiefs of Clinical Services" Course
 Harvard University School of Public Health

1993 "Epidemiology for Health Practitioners, Nutrition
 Assessment Epidemiology, Nutrition Intervention in
 Clinical Trials, Epidemiology and Health Policy" Courses
 University of Michigan School of Public Health

1993 "Advanced Epidemiological Methods" Course
 London School of Hygiene and Tropical Medicine
 University of London; London, England

1994 "Genetic Epidemiology" Course
 University of Michigan School of Public Health

RESEARCH FELLOWSHIPS:

1964-1965	NIH Medical Science Fellowship
1965	National Viets Traineeship
1966	National Multiple Sclerosis Society Fellowship
1967-1970	USPHS Traineeship in Biochemistry
1971-1972	American Academy of Pediatrics Gerber Fellowship

HONORS AND AWARDS:

1965-1967	Avalon Foundation Scholarship
1966-1970	Thurston Memorial Scholarship
1970	Phi Beta Kappa
1970	Alpha Omega Alpha
1970	Borden Undergraduate Research Award
1970	Graduated Cum Laude
1985	Fogarty Senior International Fellowship Award
2001	Joseph B. Goldberger Award in Clinical Nutrition American Medical Association
2005	Paul di Sant' Agnese Distinguished Scientific Achievement Award, U.S. Cystic Fibrosis Foundation
2008	Edwin L. Kendig Award, American Academy of Pediatrics and American College of Chest Physicians
2010	Presidential Citation Award, Wisconsin Medical Society

SOCIETY MEMBERSHIPS:

American Academy of Pediatrics, American Medical Association, American Pediatric Society, American Thoracic Society, European Cystic Fibrosis Society, Society for Pediatric Research

CERTIFICATIONS AND LICENSURE:

1971	National Board of Medical Examiners
1971	Medical Licensure, State of Wisconsin
1972	AEC Certification for Radionuclide Use in Patients
1977	American Board of Pediatrics
1979	Sub-Board of Neonatal-Perinatal Medicine
1986	Sub-Board of Pediatric Pulmonology
1995	Recertified in Pediatric Pulmonology

PROFESSIONAL APPOINTMENTS:

1974-1975	Senior Investigator Pediatric Metabolism Branch National Institute of Arthritis, Metabolism and Digestive Diseases National Institutes of Health Bethesda, Maryland
1975	Chief, Section on Developmental Biology and Clinical Nutrition Chief, Neonatal and Pediatric Medicine Branch National Institute of Child Health and Human Development National Institutes of Health Bethesda, Maryland
1975	Assistant Professor Department of Child Health School of Medicine and Health Sciences George Washington University Washington, D.C.
1977	Assistant Professor Department of Pediatrics Center for Health Sciences University of Wisconsin-Madison Madison, Wisconsin
1977	Director, Cystic Fibrosis Center University of Wisconsin Madison, Wisconsin
1978	Associate Professor Department of Pediatrics Center for Health Sciences University of Wisconsin Madison, Wisconsin
1978	Affiliate Scientist Wisconsin Regional Primate Research Center University of Wisconsin Madison, Wisconsin
1981	Affiliate Faculty Department of Nutritional Sciences University of Wisconsin Madison, Wisconsin
1981-1987	Director, Pediatric Pulmonary Specialized Center of Research ("Nutrition and Metabolism in Infant Lung Disease") University of Wisconsin Madison, Wisconsin
1982	Professor Department of Pediatrics University of Wisconsin Madison, Wisconsin

1983	Co-Director, Cystic Fibrosis Center University of Wisconsin Madison, Wisconsin
1985-1995	Chairman Department of Pediatrics University of Wisconsin Madison, Wisconsin
1988-1995	Medical Director University of Wisconsin Children's Hospital Madison, Wisconsin
1990-2006	Alfred Dorrance Daniels Professor on Diseases of Children University of Wisconsin Madison, WI
1992-1997	Director, Pulmonary Specialized Center of Research on Lung Biology and Diseases in Infants and Children ("Pathobiology of Bronchopulmonary Dyplasia") University of Wisconsin Madison, Wisconsin
1994	Interim Dean, Medical School University of Wisconsin Madison, WI
1995-2005	Dean, Medical School University of Wisconsin Madison, WI
2006	Dean, School of Medicine and Public Health University of Wisconsin Madison WI
2001-2006	Vice Chancellor for Medical Affairs University of Wisconsin Madison, WI
2005-2009	Robert Turell Professor in Medical Leadership University of Wisconsin Madison, WI
2006	Affiliate Faculty Department of Population Health Sciences University of Wisconsin Madison WI
2007-	Visiting Professor Department of Pediatrics University of South Florida Tampa FL

PROFESSIONAL ACTIVITIES:

1974-1977	Member, Clinical Research Committee National Institute of Child Health and Human Development
1974-1976	Lecturer, Foundation for Advanced Education in the Sciences National Institutes of Health
1974-1977	Member, Conference Committee, National Cystic Fibrosis Research Foundation
1975-1977	Member, International Research Review Panel Fogarty International Center
1975-	Reviewer of grant and contract applications for the following agencies: NIAMDD, NICHD, NHLI (NHLBI), American Lung Association, National Foundation-March of Dimes
1975	Member, Nutrition Task Force National Institute of Child Health and Human Development
1975-1977	Medical Staff, Pediatrics Section Children's Hospital, National Medical Center
1976	Co-Chairman, Cystic Fibrosis Foundation Conference on Exocrine Gland Function and Development
1976	Member, Clinical Trials Review Panel National Heart and Lung Institute
1976-1977	Co-Chairman, Steering Committee, Clinical Trial on Antenatal Steroid Therapy for the Prevention of RDS, National Heart and Lung Institute
1976-1977	Member, Advisory Committee, Lung Cell Resource Facility, American Type Culture Collection
1977	Co-Chairman, NIAMDD/NHLBI/CFF Conference on Tissue Culture Approaches to the Study of Cystic Fibrosis
1977-1980	Chairman, Conferences Committee, Cystic Fibrosis Foundation
1977-1979	Member, Nutrition Committee, Cystic Fibrosis Foundation
1977-1980	Director, Core Week Lecture Program in Neonatology, University of Wisconsin School of Medicine (III Year course)
1977-1989	Lecturer, Respiratory Pathophysiology Course, University of Wisconsin School of Medicine (II Year course)
1977-	Member, Pediatric and Neonatology Section Madison General Hospital
1978-1979	Member, South-central Wisconsin Perinatal Center Planning Committee

1978-1980	Member, Research Committee Cystic Fibrosis Foundation
1978	Member, National Workshop on Bronchopulmonary Dysplasia, Sponsored by the NHLBI, National Institutes of Health
1979-1984	Director, University of Wisconsin Pediatric Pulmonary Lab
1979-1982	Chairman, University of Wisconsin Perinatal Research Committee
1979	Reviewer, SERCA Ad Hoc Committee NICHD/NIAMDD, National Institutes of Health
1979	Member, Program Committee for the Pediatric Scientific Assembly, American Thoracic Society
1979-1981	Extramural Advisor, Case Western Reserve Cystic Fibrosis Research Center
1980	Chairman, Planning Committee for the National Symposium on the Diabetic Pregnancy in the Infant of the Diabetic Mother, University of Wisconsin
1980	Chairman, Nutrition Committee, Cystic Fibrosis Foundation
1980-1985	Member, Recommended Dietary Allowances Committee, Food and Nutrition Board National Academy of Sciences
1980	Chairman, Pregnancy and Fetal Development Task Group of the NIH Task Force on Animal Models Appropriate for Research on Diabetes Mellitus
1982	Member, American Academy of Pediatrics Infant Nutrition Task Force
1982-1984	Member, University of Wisconsin Institutional Research Grant Committee American Cancer Society
1983	Member, Wisconsin Infant Apnea Task Force
1984-1990	Member, Medical Advisory Council Cystic Fibrosis Foundation
1984-1986	Vice-Chairman, Cystic Fibrosis Foundation Research Committee
1984	Visiting Professor, Laboratoire de Physiologie du Developpement, College de France
1984-1989	Member, Editorial Board of <u>Pediatric Pulmonology</u> and Section Editor for Symposia
1985	Fogarty Senior International Fellowship Award Laboratoire de Physiologie du Developpement College de France (with Professeur Alfred Jost)
1985-	Member, Executive Committee, Wisconsin Chapter of the American Academy of Pediatrics

1985-	Member, Association of Medical School Pediatric Department Chairmen
1986-1990	Chairman, Cystic Fibrosis Foundation Research and Research Training Committee
1986-1989	American Academy of Pediatrics Mead-Johnson Award Committee
1988	Chairman, American Academy of Pediatrics Mead-Johnson Award Committee
1989-1993	Member, Editorial Board of Annual Review of Nutrition
1989-1994	President, Hearts and Hands for Children, Inc. Madison Ronald McDonald House
1990	Member, Borden Award Jury, American Institute of Nutrition
1991-	Member, Nominating Committee Association of Medical School Pediatric Department Chairmen
1994	Chairman, Nominating Committee Association of Medical School Pediatrics Department Chairman
1998-	Member, ELAM Advisory Committee (Executive Leadership in Academic Medicine Program for Woman)
1999-	Member, Veterans Administration/Council of Deans Liaison Committee
2003-	Lecturer on "Chronic Pediatric Malnutrition" in the Clinical Nutrition Course, University of Wisconsin Medical School (II Year course)
2005-2006	Course Director for "Cystic Fibrosis Newborn Screening—An Opportunity to Improve the Health of Children Through Early Diagnosis and Treatment" (CME presentation in 32 US cities)
2006-	National Facilitator for Implementation of Cystic Fibrosis Newborn Screening, U.S. Cystic Fibrosis Foundation
2006-2009	Member, Subcommittee on Newborn Screening Guidelines for Premature and/or Sick Newborns, Clinical and Laboratory Standards Institute
2007-2009	Member, Subcommittee on Sweat Testing: Sample Collection and Quantitative Chloride Analysis, Third Edition Clinical and Laboratory Standards Institute
2007-2008	Course Director for "A New Era in Cystic Fibrosis: Newborn Screening and Preventive Management" (CME Webcast program presented nationwide in 10 interactive sessions)

2008-

Chair, Subcommittee on Newborn Screening for Cystic
Fibrosis, Clinical and Laboratory Standards Institute

2008-

Chairman, Healthy Birth Initiative Steering Committee,
Wisconsin Partnership Program, University of Wisconsin
School of Medicine and Public Health

TRAINEES (STUDENTS AND FELLOWS):

1. Graduate Students

Susan M. Langan, MS (article #66)
Dorothy M Ainsworth, PhD (article #89)
Kathleen E. McMahon, MS (articles #77 and #82)
Mary S. Marcus, MS (article #104)
Julie Mares-Perelman, MS (article #84)
Molly K. Kloosterboer, MS (articles #211 and #226)
Katelyn Parker, MPH (article #227)
Janelle M. Wells, MD, MPH (article #228)

2. Medical Students

Amy Simantal, MD (articles #129 and #133)
Christopher E. Colby, MD (articles #131 and #139)
Charles Kwon, MD (article #151)
Amy Haavisto, MD (article #158)
Raymond J. Kotwicki, MD, MPH (article #160)
David J. Ciske, MD (article #158)
Joseph L. Bobadilla, MD (articles #162 and #166)
Don S. Lee, MD, MPH (article #170)
Andrew Peterson, MD (article #170)
Andrew T. Braun, MD (article #193)
Simona Joffe, MD (article #202)
Malika Siker, MD (articles #203 and #206)
Aimee Cunningham Walsh, MD (article #218)

3. Postdoctoral and Clinical Fellows in Pulmonology

T. Alan Merritt, MD (article #12)
Michael F. Epstein, MD (articles #13, #18, #23, #29, and #30)
Lawrence F. Cohen, MD (articles #27 and #28)
Sharon L. Levine, MD (articles #31 and #38)
Robert L. Manniello, MD (articles #31, #34, #39, and #40)
Dorothy B. Gail, PhD (articles #41 and #43)
Van S. Hubbard, MD, PhD (article #45)
Michael J. Engle, PhD (articles #49 and #50)
Suzzane S. Toce, MD (article #62)
Steven Blythe, MD (article #63)
Jacques R. Bourbon, PhD (article #67)
Robert E. Schumacher, MD (articles #76 and #91)
Jerry J. Zimmerman, MD, PhD (article #81)
Jeffrey Lobas, MD
Michael J. Rock, MD (articles #96 and #102)
Mark R. Weatherly, MD (article #114)
Benjamin S. Wilfond, MD, MPH (articles #115 and #117)
Andreas Van Egmond, MD (article #126)
Jack Sharp, MD
Donald Hayes, MD (articles #217 and #222)

ARTICLES:

1. Tureen LL, Farrell PM and Cova RR. Comparison of plasma protein changes in antioxidant deficiency muscular dystrophy and genetic muscular dystrophy of the chicken. *Proc Soc Exp Biol Med*, 119:28-32, 1965.
2. Farrell PM, Eyerman EL and Tureen LL. Comparison of plasma creatine phosphokinase changes in nutritional and genetic muscular dystrophy in the chicken. *Ann N.Y. Acad Sci*, 138:102-111, 1966.
3. Farrell PM and Tureen LL. Phenotypic expression in chickens heterozygous for hereditary muscular dystrophy. *Proc Soc Exp Biol Med*, 127:678-682, 1968.
4. Farrell PM and Zachman RD. Induction of choline phosphotransferase and lecithin synthesis in the fetal lung by corticosteroids. *Science*, 179:287-302, 1973.
5. Farrell PM and Zachman RD. Corticosteroids as primary therapeutic agents in respiratory distress syndrome (RDS). *Pediatrics*, 51:952-954, 1973.
6. Farrell PM and Olson RE. Creatine phosphate and adenine nucleotides in muscle from animals with muscular dystrophy. *Amer J Physiol*, 225:1102-1106, 1973.
7. Klagsbrun M and Farrell PM. The methylation of transfer and ribosomal ribonucleic acid in human fibroblasts: Normal methylation of RNA in cystic fibrosis. *Pediatr Res*, 8:205-211, 1974.
8. Farrell PM, Lundgren DW and Adams AJ. Choline kinase and choline phosphotransferase in developing fetal rat lung. *Biophys Res Comm*, 57:696-701, 1974.
9. Farrell PM, Pallavinci JC and Ulane MM. Growth characteristics and protein content of tissue cultured fibroblasts from cystic fibrosis patients. *Proc Soc Expt Biol Med*, 149:340-343, 1975.
10. Farrell PM, Fratantoni JC, Bieri JG and di Sant'Agnese, PA. Effects of vitamin E deficiency in man. *Acta Pediat Scand*, 64:150-151, 1975.
11. Farrell PM and Avery ME. State of the art - hyaline membrane disease. *Am Rev Resp Dis*, 111:657-688, 1975.
12. Epstein MF and Farrell PM. The choline incorporation pathway: Primary mechanism for de novo lecithin synthesis in fetal primate lung. *Pediatr Res*, 9:658-665, 1975.
13. Lundgren DW, Farrell PM and di Sant'Agnese PA. Polyamine alterations in blood of male homozygotes and heterozygotes for cystic fibrosis. *Clin Chem Acta*, 62:357-362, 1975.
14. Wood RE, Wanner A, Hirsch J, Newball HH and Farrell PM. Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. *Am Rev Resp Dis*, 111:733-738, 1975.
15. Farrell PM and Bieri JG. Megavitamin E supplementation in man. *Am J Clin Nutr*, 28:1281-1386, 1975.
16. Merritt TA and Farrell PM. Diminished pulmonary lecithin synthesis in acidosis: Experimental findings as related to respiratory distress syndrome. *Pediatrics*, 57:32-40, 1976.
17. Farrell PM and Wood RE. Epidemiology of hyaline membrane disease in the United States: Analysis of national mortality statistics. *Pediatrics*, 58:167-176, 1976.
18. Epstein MF, Farrell PM and Chez RA. Fetal lung lecithin metabolism in the glucose intolerant rhesus monkey pregnancy. *Pediatrics*, 57:722-728, 1976.
19. Farrell PM. Indices of fetal maturation in diabetic pregnancy. *The Lancet*, 1:596, 1976.

20. Farrell PM and Kotas RV. The prevention of hyaline membrane disease: New concepts and approaches to therapy. *Adv Pediatr*, 23:213-269, 1976.
21. Lundgren DW, Farrell PM, Cohen LF and Hankins J. Fluctuations in whole blood polyamine levels during the menstrual cycle. *Proc Soc Exp Biol Med*, 152:81-85, 1976.
22. Douglas WHJ, Jones RM and Farrell PM. Isolation of cells that retain differentiated functions in vitro: Properties of clonally isolated type II alveolar pneumonocytes. *Environ Health Perspect*, 16:83-88, 1976.
23. Farrell PM, Epstein MF, Fleischman AR, Oakes GK and Chez RA. Lung lecithin biosynthesis in the nonhuman primate fetus: Determination of the primary pathway, in vivo. *Biol Neonate*, 29:238-246, 1976.
24. Farrell PM, Rikkers H and Moel D. Cortisol-dihydrotestosterone antagonism in a patient with hypoparathyroidism and adrenal insufficiency: Apparent inhibition of bone resorption. *J Clin Endocr Metab* 42:953-957, 1976.
25. Cohen LF, Farrell PM, Lundgren DW and di Sant'Agnese PA. Sweat electrolyte levels in cystic fibrosis as determined with local and whole body collection methods, *J Pediatr*, 89:430-433, 1976.
26. Cohen LF, Lundgren DW and Farrell PM. Distribution of spermidine and spermine in blood from cystic fibrosis patients and control subjects. *Blood*, 48:469-475, 1976.
27. Farrell PM, Fox GN, Spicer SS. Determination and characterization of ciliary ATPase in the presence of serum from cystic fibrosis patients. *Pediatr Res*. 10:127-35, 1976.
28. Epstein MF, Farrell PM and Chez RA. Fetal lung lecithin metabolism and the amniotic fluid L/S ratio in rhesus monkey gestations. *Am J Obstet, Gynec*, 125:545-549, 1976.
29. Bieri JF and Farrell PM. Nutritional metabolic and clinical aspects of vitamin E. *Vit Hormones*, 34:31-75, 1977.
30. Ulane RE, Stephenson LL and Farrell PM. A rapid accurate assay for choline kinase. *Anal Biochem*, 79:526-534, 1977.
31. Epstein MF, Farrell PM, Sparks JW, Pepe G, Driscoll S and Chez RA, Maternal betamethasone and fetal growth and development in the monkey. *Am J Obstet, Gynec*, 127:261-263, 1977.
32. Levine SL, Manniello RL and Farrell PM. Familial dysautonomia: Unusual presentation in an infant of non-Jewish ancestry. *J Pediatr*, 90:79-81, 1977.
33. Farrell PM. Fetal lung development and the influence of glucocorticoids on pulmonary surfactant. *J Steroid Biochem*, 8:463-470, 1977.
34. Farrell PM, Blackburn WR and Adams AF. Lung phosphatidylcholine synthesis and cholinephosphotransferase activity in anencephalic rat fetuses with corticosteroid deficiency. *Pediatr Res*, 11:770-773, 1977.
35. Manniello RM, Adams AJ and Farrell PM, The influence of antenatal corticosteroids on hypoglycemia in newborn rats with intrauterine growth retardation. *Pediatr Res*, 11:840-844, 1977.
36. Kotas RK, Farrell PM, Ulane RE and Chez RA. Fetal rhesus monkey lung development: Lobar differences and discordances between stability and distensibility. *J Appl Physiol*, 43:92-98, 1977.

37. Farrell PM, Bieri JG, Fratantoni JC, Wood RE, Fischer VW and di Sant'Agnese PA. The occurrence and effects of human vitamin E deficiency: A study in patients with cystic fibrosis. *J Clin Invest*, 60:233-241, 1977.
38. Manniello RM and Farrell PM. Analysis of United States neonatal mortality statistics from 1968 to 1974, with specific reference to changing trends in major casualties. *Am J Obstet Gynec*, 129:667-674, 1977.
39. Manniello RM, Schulman JD and Farrell PM. Amino acid metabolism in dysmature newborn rats: Possible explanation for the antihypoglycemic effect of prenatal glucocorticoids. *Pediatr Res*, 11:1165-1166, 1977.
40. Ulane RE, Stephenson L and Farrell PM. Evidence for the existence of a single enzyme catalyzing the phosphorylation of choline and ethanolamine in primate lung. *Biochim Biophys Acta*, 531:295-300, 1978.
41. Farrell PM, Levine SL, Murphey MD and Adams AJ. Plasma tocopherol levels and tocopherol-lipid relationships in a normal population of children as compared to healthy adults. *Am J Clin Nutr*, 31:1720-1726, 1978.
42. Gail DB and Farrell PM. Measurement of phosphatidylcholine precursors, choline, ethanolamine and methionine in fetal and adult rat lung. *Lung*, 155:255-263, 1978.
43. Farrell PM and Hamosh M. The biochemistry of fetal lung development. *Clin Perinatol*, 5:197-229, 1978.
44. Curbelo V, Gail DB and Farrell PM. Determination of disaturated lecithin in rhesus monkey amniotic fluid as an index of fetal lung maturity. *Am J Obstet Gynec*, 131:764-769, 1978.
45. Epstein MF, Farrell PM, Chez RA. Lung lecithin synthesis in primates as related to respiratory distress syndrome. *J Med Primatol*. 7:339-45, 1978.
46. Farrell PM, Blackburn GK and Cefalo RC. Familial respiratory distress syndrome in three consecutive full term infants: Case reports and documentation of lung enzyme activities. *J Reprod Med*, 22:255-258, 1979.
47. Hubbard VS, Farrell PM and di Sant'Agnese PA. 25-Hydroxycholecalciferol levels in patients with cystic fibrosis. *J Pediatr* 94:84-86, 1979.
48. Farrell PM. Vitamin E deficiency in premature infants. *J Pediatr*, 95:869-872, 1979.
49. Taussig LM, Chernick V, Wood R, Farrell PM and Mellins RB. Standardization of lung function testing in children. *J Pediatr*, 97:668-676, 1980.
50. Lemanske RF, Mischler EJ, Farrell PM, Anderson C and Busse WW. Analysis of granulocyte beta-adrenergic response in cystic fibrosis: Correlation of decreased responsiveness with disease severity. *Am Rev Respir Dis*, 123:622-626, 1981.
51. Perelman RH, Engle MJ and Farrell PM. Perspectives on fetal lung development. *Lung* 159:53-80, 1981.
52. Schwartz DB, Engle MJ, Brown DJ and Farrell PM. The stability of phospholipids in amniotic fluid. *Am J Obstet Gynec*, 141:294-298, 1981.
53. Farrell RH, Engle MJ, Frantz ID, Goldman AS, Kalkoff R, Kemnitz JW, Perelman RH, Stern JS and Susa JB. Complications of pregnancy and fetal development. *Diabetes*, 31:89-94, 1982.

54. Graft D, Mischler EJ, Farrell PM and Busse WW. Granulocyte chemiluminescence in adolescent cystic fibrosis patients. *Am Rev Resp Dis*, 125:540, 1982.
55. Perelman RJ, Engle MJ, Kemnitz JW, Kotas RV and Farrell PM. Biochemical and physiological development of fetal rhesus lung. *J App Physiol*, 53:230-235, 1982.
56. Mischler EJ, Parrell S, Farrell PM and Odell GB. Effectiveness of enteric coated pancreatic enzymes compared to a conventional enzymes in males with cystic fibrosis. *Am J Dis Child*, 136:1060-1063, 1982.
57. Perelman RJ and Farrell PM. Analysis of causes of neonatal death in the United States with specific emphasis on fetal hyaline membrane disease. *Pediatrics*, 70:570-575, 1982.
58. Bourbon JR, Rieutort M, Engle MJ and Farrell PM. Utilization of glycogen for phospholipid synthesis in fetal rat lung. *Biochim Biophys Acta*, 712:2382-389, 1982.
59. Gourley GR, Farrell PM, Odell GB. Essential fatty acid deficiency following hepatic portoenterostomy for biliary atresia. *Am J Clin Nutr*, 36:1194-1199, 1982.
60. Farrell PM, Mischler EH and Gutcher GR. Evaluation of vitamin E deficiency in children with lung disease. *Ann N.Y. Acad Sci*, 393:96-106, 1982.
61. Farrell PM, Engle MJ, Zachman RD, Curet LB, Morrison JC, Rao AV and Poole K. The Collaborative Group of Antenatal Steroid Therapy: Amniotic fluid phospholipids after maternal administration of dexamethasone. *Am J Obstet Gynecol*, 145:484-490, 1983.
62. Farrell PM, Engle MJ, Zachman RD, Curet LB, Morrison JC, Rao AV, Poole WK. Amniotic fluid phospholipids after maternal administration of dexamethasone. *Am J Obstet Gynecol*. 145:484-90, 1983.
63. Farrell PM. RDS today: Advances in treatment and prevention. *J Resp Dis*, 80-100, 1983.
64. Kemnitz JW, Eisele SG, Lindsey KA, Engle MJ, Perelman RJ and Farrell PM. Changes in food intake during menstrual cycles and pregnancy of normal and diabetic Rhesus monkeys. *Diabetologia*, 26:60-64, 1984.
65. Farrell PM, Engle MJ, Perelman RJ, Curet LB, Morrison J. Saturated phospholipids in amniotic fluid of normal and diabetic pregnancies. *Obstet Gynec*, 64:77-85, 1984.
66. Toce SS, Farrell PM, Leavitt LA and Samuels DP. Clinical and radiographic scoring systems for assessing bronchopulmonary dysplasia. *Am J Dis Child*, 138:581-585, 1984.
67. Blythe S and Farrell PM. Advances in the diagnosis and management of cystic fibrosis. *Clin Biochem*, 17:277-283, 1984.
68. Gutcher GR, Lax AA and Farrell PM. Tocopherol isomers in intravenous lipid emulsions and resultant plasma concentrations. *JPEN*, 8:269-273, 1984.
69. Engle MJ, Perelman RJ, Langan S, McMahon K, Farrell PM. Relationship between the severity of experimental diabetes and altered lung phospholipid metabolism. *Proc Soc Exper Biol Med*, 176:261-267, 1984.
70. Gutcher GR, Lax A and Farrell PM. Vitamin A losses to plastic intravenous infusion devices and an improved method of delivery. *Am J Clin Nutr*. 40:8-13, 1984.
71. Gutcher GR, Raynor WJ and Farrell PM. An evaluation of vitamin E status in premature infants. *Am J Clin Nutr*, 40:1078-1089, 1984.

72. Bruno JV, McMahon KE and Farrell PM. Lung surfactant phospholipids in starvation as related to hydration and choline status. *J Nutr*, 115:85-92, 1985.
73. Farrell PM, Mischler EH, Engle MJ, Brown DJ and Lau SM. Fatty acid abnormalities in cystic fibrosis. *Pediatr Res*, 19:104-109, 1985.
74. Langan SM and Farrell PM. Vitamins E, A, and essential fatty acid status of patients hospitalized for anorexia nervosa. *Am J Clin Nutr*, 41:1054-1060, 1985.
75. Bourbon JR, Farrell PM. Fetal lung development in the diabetic pregnancy. *Pediatr Res*, 19:253-267, 1985.
76. Gutcher GR and Farrell PM. Early intravenous correction of vitamin E deficiency in premature infants. *J Ped Gastroent Nutr*, 4:604-609, 1985.
77. Perelman RH, Farrell PM, Engle MJ and Kemnitz JW. Developmental aspects of lung lipids. *Ann Rev Physiol*, 47:803-822, 1985.
78. Schumacher RE and Farrell PM. Diaphragmatic hernia: A major remaining challenge in neonatal respiratory care. *Perinatol-Neonatal*, 8:29-44, 1985.
79. McMahon KE and Farrell PM. Measurement of free choline concentrations in maternal and neonatal blood by micropyrolysis gas chromatography. *Clin Chim Acta*, 149:1-12, 1985.
80. Kemnitz JW, Perelman RJ, Engle MJ and Farrell PM. An experimental model for studies of fetal maldevelopment in the diabetic pregnancy. *Pediatr Pulm*, 1:79-85, 1985.
81. Perelman RH, Farrell PM, Engle MJ, Kemnitz JW. Developmental aspects of lung lipids. *Annu Rev Physiol*. 47:803-22, 1985.
82. Perelman RH, Engle MJ, Palta M, Kemnitz JW, Farrell PM. Fetal lung development in male and female nonhuman primates. *Pediatr Res*. 20:987-91, 1986.
83. Farrell PM, et al. Nutrition and Infant Lung Functions. *Pediatr Pulm*, 2:44-59, 1986.
84. Nondahl SR, Finlay JL, Farrell PM, Warner TF and Hong R. A case report and literature review of primary pulmonary histiocytosis X of childhood. *Med and Pediatr Onc*, 14:57-62, 1986.
85. Farrell PM, Gilbert EJ, Zimmerman JJ, Warner TF and Saari TN. Familial lung disease associated with proliferation and desquamation of type II pneumocytes. *Am J Dis Child*, 140:262-266, 1986.
86. McMahon KE and Farrell PM. The effect of choline deficiency on lung phospholipid concentrations in the rat. *J Nutr*, 116:936-943, 1986.
87. Mischler EH, Parrell SW, Farrell PM, Raynor WJ and Lemen RJ. Correction of linoleic acid deficiency in cystic fibrosis. *Pediatr Res*, 20:36-41, 1986.
88. Mares-Perelman J and Farrell PM. Changes in erythrocytes and plasma carnitine concentrations in preterm neonates. *Am J Clin Nutr*, 43:77-84, 1986.
89. Rietort M, Farrell PM, Engle MJ, Pignol B and Bourbon JR. Changes in surfactant phospholipids in fetal rat lungs from normal and diabetic pregnancies. *Pediatric Res*, 20:650-654, 1986.
90. Farrell PM and Bourbon JR. Fetal lung surfactant lipid synthesis from glycogen during organ culture. *Biochim Biophys Acta*, 878:159-167, 1986.

91. Perelman RJ, Engle MJ, Kemnitz JW, Palta M and Farrell PM. Concordance in biochemical and physiological maturation in male and female fetal Rhesus lung. *Pediatr Res*, 20:987-991, 1986.
92. Perelman RJ, Palta M, Kirby R and Farrell PM. Discordance between male/female deaths due to respiratory distress syndrome. *Pediatrics*, 78:238-244, 1986.
93. Ainsworth DM, Keith IM, Lobas JG, Farrell PM and Eicker SW. Oxygen toxicity in the infant rhesus monkey lung. Light microscopic and ultrastructural studies. *Histol Histopath*, 1:75-87, 1986.
94. Farrell PM, Mischler EH, Sondel SA and Palta M. Predigested formula in infants with cystic fibrosis. *J Am Diet Assoc*, 87:1353-1356, 1987.
95. Schumacher RE, Farrell PM and Olson EB. Circulating 5-Hydroxytryptamine concentrations in premature newborns. *Pediatric Pulm*, 3:117-122, 1987.
96. Bourbon JR, Farrell PM, Doucet E, Brown DJ and Valenza C. Biochemical maturation of fetal rat lung. A comprehensive study including surfactant determination. *Biol Neonate*, 52:48-60, 1987.
97. Farrell PM, Gutcher GR, Palta M and DeMets D. Essential fatty acid deficiency in premature infants due to delayed provision of fat-contained nutritional support. *Am J Clin Nutr*, 48:220-229, 1988.
98. Keith IM, Ekman R and Farrell PM. Oxygen toxicity in the infant rhesus monkey. Effects on regulatory peptides in lung and blood. *Ped Pulm*, 5:31-35, 1988.
99. Green CG, Kraus CK, Lemanske RF, Farrell PM and Jusk WJ. Rapid methylprednisolone clearance in cystic fibrosis. *Drug Intell Clin Pharm*, 22:876-878, 1988.
100. Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ and Laessig RH. Immunoreactive trypsinogen screening for cystic fibrosis: Characterization of infants with a false positive screening test. *Pediatr Pulm*, 6:42-48, 1989.
101. Farrell PM and Fost NC. Longterm mechanical ventilation in pediatric respiratory failure: Medical and ethical considerations. *Am Rev Resp Dis*, 140:S36-S40, 1989.
102. Mischler E, Farrell PM, Bruns T, Rock M, Tluczek A, Colby H, McCarthy C, Hassemer D, Laessig R, and Fost N. Neonatal screening for cystic fibrosis. *WI Med Jour*, 88:14-17, 1989.
103. Fost NC and Farrell PM. A prospective randomized trial of early diagnosis and treatment of cystic fibrosis: A unique ethical dilemma. *Clinical Research*, 37:495-500, 1989.
104. Uno H, Lohmiller L, Thieme C, Kemnitz J, Engle M, Farrell P. Developmental brain damage induced by prenatal treatment of dexamethasone in fetal rhesus macaques. I. Hippocampus. *Dev Brain Res*, 53:157-167, 1990.
105. Farrell PM, Bourbon JR, Notter RH, Marin L, Noguee L and Whitsett JA. Lung development in the rat: Appearance and characterization of pulmonary surfactant. *Biochim Biophys Acta*, 1044:84-90, 1990.
106. Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH, Wei LJ. Newborn screening for cystic fibrosis is complicated by the age-related decline in immunoreactive trypsinogen levels. *Pediatrics*, 85:1001-1007, 1990.
107. Palta M, Gabbert D, Fryback D, Widjaja I, Peters ME, Farrell PM and Johnson J. Development and validation of an index for scoring baseline respiratory disease in the very low birth weight neonate. *Pediatrics*, 86:714-721, 1990.

108. Marcus MS, Sondel SA, Farrell PM, Laxova A, Carey P, Langhough R and Mischler EH. Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention. *Am J Clin Nutr.* 54:578-585, 1991.
109. Farrell PM, Mischler EH, Fost NC, Wilfond BS, Tluczek A, Gregg RG, Bruns WT, Hassemer DJ and Laessig RH. Current issues in neonatal screening for cystic fibrosis and implications of the CF gene discovery. *Pediatr Pulmonol.* 57:11-18, 1991.
110. Tluczek A, Mischler EH, Bowers B, Peterson NM, Morris MC, Farrell PM, Bruns WT, Colby H, McCarthy C, Fost N and Carey P. Psychosocial impact of false-positive results when screening for cystic fibrosis. *Pediatr Pulmonol.* 57:29-37, 1991.
111. Hassemer DJ, Laessig RH, Hoffman GL and Farrell PM. Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin. *Pediatr Pulmonol.* 7:76-83, 1991.
112. Gutcher GR, Farrell PM. The early intravenous infusion of Intralipid for the correction of essential fatty acid deficiency in premature infants and the impact on bilirubin binding. *Am J Clin Nutr.* 54:1024-1028, 1991.
113. Mischler EH, Marcus MS, Sondel SA, Laxova A, Carey P, Langhough R, Farrell PM. Nutritional assessment of infants with cystic fibrosis diagnosed through screening. *Pediatr Pulmonol Suppl.* 7:56-63, 1991.
114. Farrell PM and Mischler EH. Newborn screening for cystic fibrosis. *Adv Pediatr.* 39:31-64, 1992.
115. Ramsey BW, Farrell PM and Pencharz P. Nutritional assessment and management in cystic fibrosis: a consensus report. *Am J Clin Nutr.* 55:108-16, 1992.
116. Tluczek A, Mischler EH, Farrell PM, Fost N, Peterson NM, Carey P, Bruns WT and McCarthy C. Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. *J Dev Behav Pediatr.* 13:181-186, 1992.
117. Farrell PM and Zimmerman JJ. Bronchopulmonary dysplasia. *Current Opinion in Pediatrics.* 4:410-416, 1992.
118. Farrell PM, Gilbert-Barness E, Bell J, Gregg R, Mischler E, Odell G, Shahidi N, Robertson I and Evans J. Progressive malnutrition, severe anemia, hepatic dysfunction, and respiratory failure in a three-month-old white girl. *Am J Med Genetics* 45:725-738, 1993.
119. Weatherly MR, Palmer CGS, Peters ME, Green CG, Fryback D, Langhough R and Farrell PM. Wisconsin cystic fibrosis chest radiograph scoring system. *Pediatrics* 91:488-495, 1993.
120. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D and Mischler EH. The application of DNA analysis in a population screening program for neonatal diagnosis of cystic fibrosis: comparison of screening protocols. *Am J Human Genetics* 52:616-626, 1993.
121. Farrell PM. Cystic fibrosis neonatal screening -- a continuing dilemma, especially in North America. *Screening,* 2:63-67, 1993.
122. Wilfond BS, Farrell PM, Laxova A and Mischler EH. Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis. Implications for neonatal screening. *Clin Pediatr,* 33:2-7, 1994.
123. Kosorok MR, Wei WH, Farrell PM. The incidence of cystic fibrosis after accounting for under-diagnosis. Technical Report 85. Department of Biostatistics, University of Wisconsin, Madison, Wisconsin, 1994.
124. Zimmerman JJ and Farrell PM. Advances and issues in bronchopulmonary dysplasia. *Current Problems in Pediatrics.* *Curr Probl Pediatr,* 24:159-70, 1994.

125. Farrell PM, Aronson RA, Hoffman G and Laessig RH. Newborn screening for cystic fibrosis in Wisconsin: First application of population-based molecular genetics testing. *Wisc Med J* 93:415-21, 1994.
126. Rettammel AL, Marcus MS, Farrell PM, Sondel SA, Kosciak RE and Mischler EH. Oral supplementation with a high-fat, high-calorie product improves nutritional status and alters serum lipids in patients with cystic fibrosis. *J Am Diet Assoc* 95:454-459, 1995.
127. Hoffman GL, Laessig RH, Litsheim T, Kopish G and Farrell PM. Addition of a two tiered IRT/DNA cystic fibrosis testing protocol to a routine newborn screening operation. Proceedings, 11th National Neonatal Screening Symposium, Corpus Christi, Texas, 107-111, 1995.
128. Kosorok MR, Wei WH and Farrell PM. The incidence of cystic fibrosis. *Statistics in Medicine* 15:449-462, 1996.
129. Farrell PM and Kosciak RE. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. *Pediatrics* 97:524-528, 1996.
130. Allen DB and Farrell PM. Newborn Screening. *Adv Pediatr*, 43:231-270, 1996.
132. van Egmond AWA, Kosorok MR, Kosciak R, Laxova A and Farrell PM. Effect of linoleic acid intake on growth of infants with cystic fibrosis. *Am J Clin Nutr* 63:746-752, 1996.
133. Foster SW and Farrell PM. Enhancing nutrition in cystic fibrosis with comprehensive therapies. *J Pediatr Gastroenterol Nutr*, 22:238-239, 1996.
134. Engle MJ, Kemnitz JW, Rao TJ, Perelman RH and Farrell PM. Effects of maternal dexamethasone therapy on fetal lung development in the Rhesus monkey. *Am J Perinatol* 13:399-407, 1996.
135. Farrell PM, Gregg RG, Simantel A, et al. Molecular aspects of newborn screening for cystic fibrosis in Wisconsin. Proceedings Third Meeting of the International Society for Neonatal Screening, pp. 43-47, 1996.
136. Farrell PM, Shen G, Splaingard M, Colby CE, Laxova A, Kosorok MR and Rock, MJ. Acquisition of *Pseudomonas aeruginosa* in children with cystic fibrosis. *Pediatrics* 100:/5/e2, 1997.
137. Farrell PM, Kosorok MR, Laxova A, Shen G, Kosciak RE, Bruns, T, Splaingard M and Mischler EH. Nutritional benefits of newborn screening for cystic fibrosis. *New Eng J Med* 337:963-969, 1997.
138. Gregg RG, Simantel A, Farrell PM, Kosciak RE, Kosorok MR, Laxova A, Laessig RH, Hoffman GL, Hassemer DJ, Mischler EH, Splaingard M. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. *Pediatrics* 99:819-824, 1997.
139. Stoddard JJ and Farrell PM. State-to-state variations in newborn screening policies. *Arch Pediatr Adol Med* 151:561-564, 1997.
140. Farrell PM. Avenues for child advocacy. *The Pharos of Alpha Omega Alpha* 61:38-42, 1997.
141. Farrell PM. Centers for Disease Control and Prevention. Newborn screening for cystic fibrosis: a paradigm for public health genetics policy development--proceedings of a 1997 workshop. *MMWR* 46(No. RR-16): 11-12, 1997.
142. Palta M, Sadek M, Barnet JH, Evans M, Weinstein MR, McGuinness G, Peters ME, Gabbert D, Fryback D, and Farrell PM. Evaluation of criteria for chronic lung disease in surviving very low birth weight infants. *J Pediatr* 132:57-63, 1998.

143. Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG, Shen G, Walker S and Farrell PM. Growth status in children with cystic fibrosis based on the national cystic fibrosis patient registry data: evaluation of various criteria used to identify malnutrition. *J Pediatr* 132:478-485, 1998.
144. Mischler EH, Wilfond BS, Fost N, Laxova A, Reiser C, Sauer C, Makhholm L, Shen G, Feenan L, McCarthy C, and Farrell PM. Cystic fibrosis newborn screening: impact on reproductive decision making and implications for genetic counseling. *Pediatrics* 102:44-52, 1998.
145. Kosorok MR, Jalaluddin M, Farrell PM, Shen G, Colby CE, Laxova A, Rock MJ, and Splaingard M. Comprehensive analysis of risk factors for acquisition of *Pseudomonas aeruginosa* in young children with cystic fibrosis. *Pediatr Pulmonol* 26:81-88, 1998.
146. Albanese M, Horowitz S, Moss R, and Farrell P. Outcomes of an institutionally funded educational research and development grants program: It makes dollars and sense. *Acad Med* 73:756-761, 1998.
147. Farrell PM. Benefits of neonatal screening for cystic fibrosis. *Biomed & Pharmacother* 52:411-412, 1998.
148. Lai HC, Corey M, FitzSimmons S, Kosorok MR, and Farrell PM. Comparison of growth status in patients with cystic fibrosis between United States and Canada. *Amer J Clin Nutr* 69:1-8, 1999.
149. Farrell PM. Four great Wisconsin ideas, part one: how the University of Wisconsin-Madison achieved world-class status. *Wisc Acad Rev* 45:7-15, 1999.
150. Farrell PM. Four great Wisconsin ideas, part two: implications and challenges for the twenty-first century. *Wisc Acad Rev* 46:53-58, 1999.
151. Lai HC, Kosorok MR, Laxova A, Davis LA, FitzSimmon SC, and Farrell PM. Nutritional Status of Patients with Cystic Fibrosis with Meconium Ileus: A comparison with patients without meconium ileus and diagnosed early through neonatal screening. *Pediatrics* 105:53-61, 2000.
152. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, and Farrell PM. Persistent growth impairment in children with cystic fibrosis following treatment with alternate-day prednisone. *New Eng J Med* 342:851-859, 2000.
153. Bonazza J, Farrell PM, Albanese M, and Kindig D. Collaboration and peer review in medical school strategic planning. *Acad Med* 75:409-418, 2000.
154. Kwon C and Farrell PM. The magnitude and challenge of false-positive newborn screening test results. *Arch Pediatr Adolesc Med* 154:714-718, 2000.
155. Kosciak RE, Kosorok MR, Farrell PM, Collins J, Peters ME, Laxova A, Green CG, Zeng L, Rusakow LS, Hardie RC, Campbell RW, and Gurney JW. The Wisconsin cystic fibrosis chest radiograph scoring system: validation and standardization for application to longitudinal studies. *Pediatr Pulmonol* 29:457-467, 2000.
156. Farrell PM and the Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Improving the health of patients with cystic fibrosis through newborn screening. *Adv Pediatr*, 47:79-115, 2000.
157. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, Hoffman G, Laessig RH, and Splaingard ML. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. *Pediatrics* 107:1-12, 2001.
158. Farrell MH, Certain LK, and Farrell PM. Genetic counseling and other risk communication services by newborn screening programs. *Arch Pediatr Adol Med* 155:120-126, 2001.

159. Ciske DJ, Haavisto A, Laxova A, Zeng L, Rock MJ, and Farrell PM. Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process. *Pediatrics* 107:699-705, 2001.
160. Kosorok MR, Zeng L, West SHE, Rock MJ, Splaingard ML, Laxova A, Green, CG, Collins, J, and Farrell PM. Acceleration of lung disease in children with cystic fibrosis after *Pseudomonas aeruginosa* acquisition. *Pediatr Pulmonol* 32:277-287, 2001.
161. Kotwicki RJ, Condra L, Vermeulen L, Wolf T, Douglas JA, and Farrell PM. Assessing the quality of life in children with cystic fibrosis. *Wisc Med J* 100:50-54, 2001.
162. Wagener JS, Farrell PM and Corey M. Commentary: why my state (province) should conduct newborn screening for cystic fibrosis (14th Annual North American Cystic Fibrosis Conference). *Pediatr Pulmonol* 32:385-396, 2001.
163. Bobadilla JL, Macek M, Fine JP, and Farrell PM. Cystic fibrosis: a worldwide analysis of *CFTR* mutations – correlation with incidence data and application to screening. *Human Mutation* 19:575-606, 2002.
164. Banwart B, Splaingard ML, Farrell PM, Rock MJ, Havens PL, Moss J, Ehrmantraut ME, Frank DW and Barbieri JT. Children with cystic fibrosis produce an immune response against ExoS, a type-III cytotoxin of *P. aeruginosa*. *J Infect Dis* 185:269-270, 2002.
165. Ridley GT, Skochelak SE, and Farrell PM. Mission aligned management and allocation: A successfully implemented model of mission-based budgeting. *Acad Med* 77:124-129, 2002.
166. Lai HC, Kosorok MR, Laxova A, Makhholm LM and Farrell PM. Delayed diagnosis in females with cystic fibrosis in the United States. *Am J Epidemiol* 156:165-173, 2002.
167. Bobadilla JL, Farrell MH and Farrell PM. Applying CFTR molecular genetics to facilitate the diagnosis of cystic fibrosis through neonatal screening. *Adv Pediatr* 49:131-190, 2002.
168. West SHE, Zeng L, Bee LL, Kosorok MR, Laxova A, Rock MJ, Splaingard MJ, and Farrell PM. Respiratory infections with *Pseudomonas aeruginosa* in children with cystic fibrosis: Early detection by serology and assessment of risk factors. *J Am Med Assoc* 287:2958-2967, 2002.
169. Farrell PM and Fost NC. Prenatal screening for cystic fibrosis: Where are we now? *J Pediatr* 141:758-63, 2002.
170. Albanese MA, Snow MH, Skochelak SE, Huggett KN, and Farrell PM. Assessing personal qualities in medical school admissions. *Acad Med* 78:1-10, 2003.
171. Lee DS, Rosenberg MA, Peterson A, Makhholm LM, Hoffman G, Laessig RH, and Farrell PM. Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program. *J Pediatr* 142:617-23, 2003.
172. Albanese MA, Snow M, Skochelak S, Huggett K, and Farrell PM. Matriculating student perceptions of changes to the admissions interview process at the University of Wisconsin Medical School: A prospective, controlled comparison. *Wisc Med J.* 102: 30-3, 2003.
173. Farrell PM, Li Zhanhai, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makhholm LM, Rock MJ, and Splaingard ML. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. *Pediatr Pulmonol.* 36:1-11, 2003.
174. Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai H-C, Rock MJ and Splaingard ML. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. *Am J Resp Crit Care Med.* 168:1100-1108, 2003.

175. Farrell MH, Farrell PM. Newborn screening for cystic fibrosis: Ensuring more good than harm. *J Pediatr* 143:707-712, 2003.
176. Kosciak RL, Farrell PM, Kosorok MR, Zaremba KM, Laxova A, Lai HC, et al. Cognitive function of children with cystic fibrosis: deleterious effect of malnutrition. *Pediatr* 113:1549-1558, 2004.
177. Dillard JP, Carson CL, Bernard CJ, Laxova A, and Farrell PM. An analysis of communication following newborn screening for cystic fibrosis. *Health Communication*, 16:195-206, 2004.
178. Lai, HC, Cheng Y, Cho H, Kosorok MR, and Farrell PM. Association between initial disease presentation, lung disease outcomes and survival in patients with cystic fibrosis. *Am J Epidemiol* 159:537-546, 2004.
179. Li Z, Kosorok MR, Farrell PM, Laxova A, West SHE, Green CG, Collins J, Rock MJ, and Splaingard ML. Longitudinal development of *Pseudomonas aeruginosa* infection and lung disease progression in children with cystic fibrosis. *Pediatr Pulmonol* 38:277-284, 2004.
180. Johnson SC, Marshall DJ, Harms G, Miller CM, Sherrill CB, Beaty EL, Lederer SA, Roesch EB, Madsen G, Hoffman GL, Laessig RH, Kopish GJ, Baker MW, Benner SA, Farrell PM, Prudent JR. Multiplexed genetic analysis using an expanded genetic alphabet. *Clinical Chemistry*, 50:2019-2027, 2004.
181. Farrell PM. Cystic fibrosis newborn screening: Shifting the key question from “Should we screen?” to “How should we screen?” *Pediatrics*, 113:1811-1812, 2004.
182. Li A, Lai HC, Kosorok MR, Laxova A, Rock MJ, Splaingard ML, Farrell PM. Longitudinal pulmonary status of cystic fibrosis children with meconium ileus. *Pediatr Pulmonol*, 38:277-284, 2004.
183. Li Z, Kosorok MR, Farrell PM, Laxova A, West SHE, Green CG, Collins J, Rock MJ, and Splaingard ML. Longitudinal development of mucoid *Pseudomonas aeruginosa* infection and lung disease progression in children with cystic fibrosis. *JAMA*, 293:581-588, 2005.
184. Albanese MA, Farrell PM, Dottl SL. A comparison of statistical criteria for setting optimally discriminating MCAT and GPA thresholds in medical school admissions. *Teaching and Learning in Medicine* 17:149-158, 2005.
185. Tluczek A, Kosciak RL, Farrell PM, and Rock MJ. Psychosocial risk associated with newborn screening for cystic fibrosis: parents’ experience while awaiting sweat test appointment. *Pediatrics*, 115:1692-1703, 2005.
186. Albanese MA, Farrell PM, Dottl SK. Statistical Criteria for setting thresholds in medical school admissions. *Advances in Health Sciences Education* 10:89-103, 2005.
187. Corech R, Rao A, Laxova A, Moss J, Rock MJ, Li Z, Kosorok MR, Splaingard ML, Farrell PM, Barbieri JT. Early immune response to the Type-III System of *Pseudomonas aeruginosa* in children with cystic fibrosis. *J Clin Microbiol* 43:3096-3062, 2005.
188. Farrell PM, Lai HC, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, and Splaingard ML. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: Enough is enough. *J Pediatr* 147:S30-S36, 2005.
189. Kosciak RL, Douglas JA, Zaremba K, Rock MJ, Splaingard ML, Laxova A, and Farrell PM. Quality of life of children with cystic fibrosis. *J Pediatr* 147:S64-S68, 2005.
190. Kosciak RL, Lai HC, Laxova A, Zaremba KM, Kosorok MR, Douglas JA, Rock MJ, Splaingard ML, Farrell PM. Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. *J Pediatr* 147:S51-S56, 2005.

191. Rock MJ, Hoffman GL, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM. Newborn screening for cystic fibrosis in Wisconsin: nine years' experience with routine trypsinogen/DNA testing. *J Pediatr* 147:S73-S77, 2005.
192. Rosenberg MA and Farrell PM. Assessing the cost of cystic fibrosis diagnosis and treatment. *J Pediatr* 147:S101-S105, 2005.
193. Lai HC, Cheng Y and Farrell PM. The survival advantage of cystic fibrosis patients diagnosed through neonatal screening: Evidence from the US Cystic Fibrosis Foundation Registry data. *J Pediatr* 147:S57-S63, 2005.
194. Braun AT, Farrell PM, Ferec C, Audrezet MP, Laxova A, Li Z, Kosorok MR, Rosenberg MA, Gershan WM. Cystic fibrosis mutations and genotype-pulmonary phenotype analysis. *J Cystic Fibrosis* 5:33-41, 2006.
195. Farrell PM, Goven JRW. Pseudomonas serology: confusion, controversy, and challenges. *Thorax* 61:645-647, 2006.
196. Tluczek A, Kosciak RL, Modaff P, Pfeil D, Rock MJ, Farrell PM. Newborn screening for cystic fibrosis: Parents' preferences regarding counseling at the time of infants' sweat test. *J Genet Couns* 15:277-291, 2006.
197. Brody AS, Kosorok MR, Li A, Broderick LS, Foster JL, Laxova A, Bandla H, Farrell PM. Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. *J Thoracic Imaging*. 21:14-21, 2006.
198. Grosse SD, Rosenfeld M, Devine OJ, Lai HC, Farrell PM. Potential impact of newborn screening for cystic fibrosis on child survival: A systematic review and analysis. *J Pediatr*. 149:362-366, 2006.
199. Dillard JP, Shen L, Tluczek A, Modaff M, Farrell PM. The effect of disruptions during counseling on recall of genetic risk information: The case of cystic fibrosis. *J Genet Couns*. 16:179-190, 2007.
199. Farrell, PM. The meaning of "early" diagnosis in a new era of cystic fibrosis care. *Pediatr*. 119: 156-7, 2007.
200. Ferec C, Casals T, Chuzhanova N, Macek M, Barton D, Castellani C, Farrell PM, Sheridan M, Pantaleo SJ, Loumi O, Messaoud T, Cuppens H, Toricelli F, Cutting GR, Williamson R, Ramos MJA, Pignatti PF, Ragueneas O, Cooper DN, Audrezet MP, Chen JM. Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of their underlying mechanisms. *Eur J Hum Genet*. 14:567-576, 2007.
201. Comeau AM, Accurso FJ, White TB, Campbell PW, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Borowitz D, Massie J, Farrell PM, O'Sullivan B. Guidelines for implementation of cystic fibrosis newborn screening programs. Cystic Fibrosis Foundation working report. *Pediatr*. 119:495-518, 2007.
202. Farrell PM, Joffe S, Foley L Canny G, Mayne P, Rosenberg M. Diagnosis of cystic fibrosis in the Republic of Ireland: Epidemiology and costs. *Irish Med J*. 100:557-560, 2007.
203. Farrell P, Le Marechal C, Ferec C, Siker M, and Teschler-Nicola M. Discovery of the principal cystic fibrosis mutation (F508del) in ancient DNA from Iron Age Europeans. *Nature Precedings*. <http://hdl.nature.com/10101/npre.2007.1276.1> , 2007.
204. Rosenberg MA, Farrell PM. Predictive Modeling of costs for a chronic disease with acute high cost episodes. *North American Actuarial J*. 12: 1-18, 2008.

205. Farrell, PM Is newborn screening for cystic fibrosis a basic human right? *J Cyst Fibros.* 7:262-265, 2008.
206. Shafer MM, Siker M, Overdier JT, Ramsi PC, Teschler-Nicola M, Farrell PM. Enhanced methods for assessment of the trace element composition of Iron Age bone. *Sci Total Env.* 401: 144-161, 2008.
207. Farrell PM, Beryl J, Rosenstein BJ, White TW, Accurso FJ, Castellani C, Cutting GR, Durie PR, Vicki A, LeGrys VA, Massie J, Rock MJ,, Campbell PW, and participants in the CF Foundation Consensus Conference. Guidelines for diagnosis of cystic fibrosis in the era of newborn screening. *J Pediatr.* 153: S4-S14, 2008.
208. Farrell PM. The prevalence of cystic fibrosis in the European Union. *J Cystic Fibrosis.* 7:450-453, 2008.
209. Dillard JP, Shen L, Laxova A and Farrell PM. Threats to the effectiveness of genetic risk communication: The case of cystic fibrosis. *J Health Comm.* 23:234-44, 2008.
210. Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, de Monestrol I, Farrell P, Feilcke M, Férec C, Gartner S, Gaskin K, Hammermann J, Kashirskaya N, Loeber G, Macek M Jr, Mehta G, Reiman A, Rizzotti P, Sammon A, Sands D, Smyth A, Sommerburg O, Torresani T, Travert G, Vernooij A, Elborn S. European best practice guidelines for cystic fibrosis neonatal screening. *J Cyst Fibros.* 8:153-73, 2009.
211. Kloosterboer M, Hoffman G, Rock MJ, Gershan W, Laxova A, Li Z, Farrell, PM. Clarification of laboratory variables influencing CF newborn screening with initial analysis of immunoreactive trypsinogen. *Pediatr.* 123(9): e338-346, 2009.
212. Lai HC, Shoff SM, Farrell PM and the Wisconsin CF Neonatal Screening Group. Recovery of birth weight z-score within two years of diagnosis is positively associated with pulmonary status at age six years in children with cystic fibrosis. *Pediatr.* 123: 714-722. 2009.
213. Rao AR, Laxova A, Farrell PM, and Barbieri JT. Proteomic identification of OprL as a seromarker for the initial diagnosis of *Pseudomonas aeruginosa* infection of patients with cystic fibrosis. *J Clinical Microbiology.* 47:2483-8, 2009.
214. Farrell PM, Collins J, Broderick LS, Rock MJ, Li Z, Kosorok MR, Laxova A, Gershan WM, and Brody AS. Association between mucoid pseudomonas infection and bronchiectasis in children with CF. *Radiology.* 252:534-43, 2009.
215. Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell MP, Marshall BC, Accurso FJ. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. *J Pediatr.* 155:S73-S93, 2009.
216. Borowitz D, Parad R, Sharp JK, Sabadosa K, Robinson KA, Rock M, Farrell P, Sontag M, Rosenfeld M, Davis S, Marshall B, Accuroso F and other contributors. Cystic fibrosis foundation practice guidelines for the management of infants with CFTR-related metabolic syndrome during the first two years of life and beyond. *J Pediatr.* 155:S106-S116, 2009.
217. Hayes D, Farrell PM, Li Z, and West SE. *Pseudomonas aeruginosa* serological analysis in young children with cystic fibrosis diagnosed through newborn screening. *Pediatr Pulmonol.* 45:55-61, 2010.
218. Walsh AC, Rault G, Li Z, Scotet V, Duguépérroux I, Férec C, Roussey M, Laxova A, Farrell PM and the participating CF centres of Brittany, France. Pulmonary outcome differences in U.S. and French cystic fibrosis cohorts diagnosed through newborn screening. *J Cyst Fibros.* 9:44-50, 2010.

219. Cavanagh L, Compton CJ, Tluczek A, Brown RL, and Farrell PM. Long-term evaluation of genetic counseling following false-positive newborn screen for cystic fibrosis. *J Genet Counsel.* In press.
220. Dillard JP, Shen L, Robinson JD, and Farrell PM. Parental information seeking following a positive newborn screening for cystic fibrosis. *J Health Commun.* In press.
221. Quemener S, Chen JM, Chuzhanova N, Benech C, Casals T, Macek M, Bienvenu T, King C, Farrell PM, Loumi O, Messaoud T, Cuppens H, Cutting GR, Stenson P, Giteau K, Audrezet MP, Cooper DN, and Ferec C. Complete ascertainment of intragenic copy number mutations (CNMs) in the *CFTR* gene and its implications for CNM formation at other autosomal loci. *Human Mutations.* In press.
222. Hayes D, West SE, Rock MJ, Li Z, Splaingard ML, and Farrell PM. Longitudinal assessment of *Pseudomonas aeruginosa* in children with cystic fibrosis diagnosed through newborn screening. *Pediatr Pulmonol.* In press.
223. Earley MC, Laxova A, Farrell PM, Driscoll-Dunn R, Mogayzel P, Konstan M, Hannon WH. Development of a DNA-based CF newborn screening proficiency testing program. Submitted to *Genetics in Med*
224. Goose M, Reynolds R, Li Z, and Farrell PM. Opportunities for quality improvement in cystic fibrosis newborn screening. *J Cyst Fibrosis.* In press.
225. LeGrys VA, McColley SA, Li Z, and Farrell PM. The need for quality improvement in sweat testing infants following newborn screening for cystic fibrosis. Submitted to *J Pediatr.*
226. Kloosterboer M, Reynolds R, Farrell PM, with PFMEA Teams. Innovative strategies for quality improvement in newborn screening for CF. Submitted to *Pediatr.*
227. Parker K, Rosenberg M, and Farrell P. National assessment of cystic fibrosis center accessibility. Submitted.
228. Wells JM, Rosenberg M, Hoffman G, Anstead M, and Farrell P. A decision-tree approach for a comprehensive cost comparison of two newborn screening strategies for cystic fibrosis. Submitted.

CHAPTERS:

1. Klagsbrun M and Farrell PM. The methylation of RNA in fibroblasts of normal volunteers and patients with cystic fibrosis. In Managos JA and Talamo RC, Eds. *Fundamental Problems of Cystic Fibrosis and Related Diseases*, New York, Intercontinental Medical Book Corp, pp. 53-61, 1973.
2. Farrell PM. Regulation of pulmonary lecithin synthesis. In Vilee CA, Jr., Vilee DB and Zuckerman JE, Eds. *Respiratory Distress Syndrome*, New York, Academic Press, pp. 311-341, 1973.
3. di Sant'Agnese PA and Farrell PM. Neonatal and general aspects of cystic fibrosis. In Young DC and Hicks JM, Eds. *Current Topics in Clinical Chemistry-Clinical Biochemistry of the Neonate*. New York, John Wiley and Sons, pp. 199-217, 1976.
4. Farrell PM and Morgan TE. Lecithin biosynthesis in the developing lung. In Hodson WA, Ed. *Development of the Lung*. New York, Marcel Dekker, pp. 309-366, 1977.
5. Epstein MF, Farrell PM and Chez RA. Lung lecithin synthesis in primates as related to respiratory distress syndrome. In Goldsmith EI and Moor-Jankowski J, Eds. *Advances in Medical Primatology*, New York, Basel, Karger, 1977.

6. Farrell PM and Lundgren DW. Recent observations concerning RNA methylation and polyamine metabolism in cystic fibrosis. In Mangos JA and Talamo RC, Eds. *Cystic Fibrosis: Projections into the Future*, New York, Intercontinental Medical Book Corp, pp. 223-241, 1976.
7. Farrell PM. Metabolic control of lecithin biosynthesis in developing lung. In Stern L, Ed. *Lung maturation and the prevention of hyaline membrane disease*. Columbus, Ross Laboratories, pp. 188-203, 1976.
8. Farrell PM. Vitamin E in human health and disease, In Machlin LJ, Ed. *Vitamin E*. New York, Marcel Dekker, pp. 519-620, 1976.
9. Farrell PM and Avery ME. Hyaline membrane disease. In Murray JD, Ed. *Lung Disease - State of the Art, 1974-1975*. New York, American Lung Association, pp. 1-32, 1976.
10. Douglas WHJ, Del Vecchio P, Teek RW, Jones RM and Farrell PM. Culture of type II alveolar lung cells. In Bouhuys A, Ed. *Lung Cells in Disease*. Amsterdam Elsevier/North Holland Biomedical Press, pp. 53-67, 1976.
11. Farrell PM and Zachman RD. Pulmonary surfactant and the respiratory distress syndrome. In Kretzmer N and Quilligan EJ, Eds. *Fetal & Maternal Medicine*, New York, J Wiley & Sons, pp. 221-241, 1980.
12. Farrell PM and Nitzen M. The effects of adrenal corticosteroids on the fetus with particular reference to fetal lung maturation. In Laron Z and Tikva P, Eds. *Pediatric and Adolescent Endocrinology*, Basel S, Karger, 5:88-109, 1979.
13. Farrell PM and Perelman RJ. The development of the respiratory system. In Martin RJ and Fanaroff AA, Eds. *Behrman's Textbook of Neonatal-Perinatal Medicine*, Third Edition, St. Louis, Mosby Company, pp. 404-419.
14. Farrell PM and Ulane RE. The regulation of lung phospholipid metabolism in the developing fetus. In Minkowski A, Ed. *The Physiological and Biochemical Basis for Perinatal Medicine*, Basel S, Karger, pp. 30-41, 1981.
15. Farrell PM. Lung Development and Hyaline Membrane Disease. In Farrell P, Ed. *Lung Development: Biological and Clinical Perspectives, Vol. 1, Biochemistry and Physiology*, Academic Press, New York, pp. 3-9, 1982.
16. Farrell PM. Morphologic Aspects of Lung Maturation. In Farrell P, Ed. *Lung Development: Biological and Clinical Perspectives, Vol 1, Biochemistry and Physiology*, Academic Press, New York, pp. 13-25, 1982.
17. Farrell PM. General Features of Phospholipid Metabolism in the Developing Lung. In Farrell P, Ed. *Lung Development: Biological and Clinical Perspectives, Vol. 1, Biochemistry and Physiology*, Academic Press, New York, pp. 223-238, 1982.
18. Farrell PM. The Regulation of Saturated Phosphatidylcholine Synthesis in the Developing Lung. In Farrell P, Ed. *Lung Development: Biological and Clinical Perspectives, Vol. I, Biochemistry and Physiology*, Academic Press, New York, pp. 223-238, 1982.
19. Farrell PM. Overview of Hyaline Membrane Disease. In Farrell P, Ed. *Lung Development: Biological and Clinical Perspectives, Vol II, Neonatal Respiratory Distress*, Academic Press, New York, pp. 23-46, 1982.
20. Farrell PM. Long-Term Consequences of Hyaline Membrane Disease. In Farrell P, Ed. *Lung Development: Biological and Clinical Perspectives, Vol II, Neonatal Respiratory Distress*, Academic Press, New York, pp. 23-46, 1982.

21. Farrell PM: Design and Organization of a Multicenter Clinical Trial for the Study of Corticosteroid Effects on Human Lung Development. In Farrell P, Ed. Lung Development: Biological and Clinical Perspectives, Vol. II, Neonatal Respiratory Distress, Academic Press, New York, pp. 267-273, 1982.
22. Farrell PM. Current Recommendations for Use of Prenatal Corticosteroids Based on Assessment of the Risk-Benefit Relationship. In Farrell, P, Ed. Lung Development: Biological and Clinical Perspectives, Vol. II, Neonatal Respiratory Distress, Academic Press, New York, pp. 297-300, 1982.
23. Farrell PM and Hubbard VS. In Lloyd-Still, JD, Ed. Textbook of Cystic Fibrosis, John Wright - PSG, Inc., Boston, pp. 263-294, 1983.
24. Farrell PM. Bronchopulmonary dysplasia. In Kumar S and Rathi ML, Eds. Clinical Aspects of Perinatal Medicine, MacMillan, New York, pp. 42-48, 1985.
25. Farrell PM. Fetal lung development in relationship to neonatal respiratory distress. In Kumar S and Rathi ML, Eds. Clinical Aspects of Perinatal Medicine, MacMillan, New York, pp. 85-87, 1985.
26. Farrell PM. Cystic Fibrosis. In Mellins R, Ed. Ten Year Review of Advances in Pediatric Pulmonary Disease, Government Printing Office, Washington, D.C.
27. Kemnitz JW, Houser WD, Eisele SB, Engle MJ, Perelman RJ and Farrell PM. Pregnancy and fetal development in the rhesus monkey. I. Maternal metabolism and fetal growth. In Nathanielsz, PW and Paper JT, Ed. Animal Models in Fetal Medicine. Perinatology Press, pp. 2-25, 1984.
28. Engle MJ, Perelman RJ, Kemnitz JW and Farrell PM. Pregnancy and fetal development in the rhesus monkey. II. Fetal lung maturation. In Nathanielsz PW and Paper JT, Eds. Animal Models in Fetal Medicine. Perinatology Press, pp. 29-53, 1984.
29. Perelman RH, Engle MJ, Kemnitz JW, MacDonald MJ and Farrell PM. The use of nonhuman primate (*Macaca mulatta*) for assessing fetal lung development in pregnancies complicated by streptozotocin-induced glucose intolerance. Lessons from Animal Diabetes (E. Shafrir and A. Renold, eds.) John Libbey & Co. Ltd., London, pp. 739-744, 1984.
30. Farrell PM, Zachman PM, Gutcher GR. Fat soluble vitamin A, E, and K in the premature infant. In Tsang RC, Ed. Vitamin/Mineral Levels and Premature Infancy. Marcel Dekker, New York, pp. 63-98, 1985.
31. Engle MJ and Farrell PM. Lung phospholipids in aging primates. In Davis RT and Leathers CW, Eds. Behavior and Pathology of Aging in Rhesus Monkeys. Alan R. Liss, pp. 275-292, 1985.
32. Farrell PM and Perelman RJ. The development of the respiratory system. In: Martin RJ and Fanaroff AA, Eds. Behrman's Textbook of Neonatal-Perinatal Medicine, Third Edition, St. Louis, Mosby Company, pp. 409-419, 1987.
33. Farrell PM. Vitamin E. In: Shils M and Young V. Modern Nutrition in Health and Disease (7th Ed.). Lea & Febiger, Philadelphia, pp. 340-354, 1988.
34. Kemnitz JW, Engle MJ, Flitsch TJ, Perelman RH and Farrell PM. Obesity in Pregnancy: Consequences for maternal glucose regulation and fetal growth. In: Kemnitz J, Ed. Nonhuman Primate Studies on Diabetes, Carbohydrate Intolerance, and Obesity. Alan R. Liss, pp. 29-41, 1988.
35. Farrell PM, Mischler EH, Bruns WT, Rock M, Hassemer D, Laessig RH, Fost N, DeMets D. False positive results using IRT as a screening test for cystic fibrosis. In: Proceedings of Conference Internationale Mucoviscidose: Dépistage néonatal et prise en charge précoce. Caen, France, pp. 59-68, October, 1988.

36. Greer FR, Zachman RD, Farrell PM. The fat soluble vitamins A, D, K, and E. In: Cowett RM, Ed. Principles of Perinatal-Neonatal Metabolism. Springer-Verlag, New York, NY, pp. 531-558, 1991.
37. Farrell PM, Mischler EH, Wilfond BS, Fost NC, Bruns WT, Splaingard ML, Wei LJ, Langhough R, Hassemer DJ, Laessig RH and Gregg RG. Neonatal screening for cystic fibrosis: clinical features, evaluation of testing procedures, and randomized investigation of benefits and risks. In: Wilcken B. and Webster D., eds. Neonatal Screening in the Nineties, Kelvin Press, New South Wales, pp. 156-165, 1991.
38. Farrell PM and Roberts RJ. Vitamin E. In: Shils M, Shike, Olson J. Modern Nutrition in Health and Disease (8th Ed). Lea & Febiger, Philadelphia, pp. 326-341, 1993.
39. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Hoffman G. et al. Assessment of the benefits, risks and costs of cystic fibrosis screening in Wisconsin, USA. In: Travert G and Wursteisen B (eds). Neonatal Screening for Cystic Fibrosis. Presses Universitaires de Caen, pp. 239-253, 1999.
40. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Hoffman G, Laessig, RH, and Splaingard ML. Newborn screening for cystic fibrosis: a paradigm for public health genetics policy development. In: Khoury MJ, Burke W, and Thomson E. Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease. Oxford University Press, pp. 405-429, 2000.
41. Lai HC and Farrell PM. Nutrition and cystic fibrosis. In: Rock C and Monsen E (eds). Nutrition in the Prevention and Treatment of Disease. Academic Press, New York, pp. 715-727, 2001.
42. Farrell PM. Neonatal Screening: Toward earlier diagnosis and improved outcome. In: Doershuk C. Cystic Fibrosis in the 20th Century. AM Publishing, Cleveland, pp.120-137, 2001.
43. Farrell PM. The advantages of universal CF neonatal screening: Why we need it. In: Doershuk C. Cystic Fibrosis in the 20th Century. AM Publishing, Cleveland, pp.391-394, 2001.
44. Farrell PM and Lai HC. Nutrition and Cystic Fibrosis. In: Coulston AM and Boushey CJ, eds., Nutrition in the Prevention of Disease, Chapter 45, Academic Press, New York, pp. 715-727, 2001.
45. Rock MJ and Farrell PM. Neonatal screening for cystic fibrosis. In: Chernick/Boat/Wilmott/Bush: Kendig's Disorders of the Respiratory Tract in Children. Seventh Ed., Chapter 59, Elsevier, USA, pp.861-865, 2006.
46. Farrell PM and Elias S. Prenatal diagnosis and neonatal screening. In E. Gilbert-Barness (Ed.). Potter's Pathology of the Fetus, Infant and Child, Second Edition, Mosby Elsevier, New York, pp. 611-644, 2007.
47. Lai HC and Farrell PM. Nutrition and CF. In: Coulston AM and Boushey CJ, eds., Nutrition in the Prevention of Disease, Second Edition, Chapter 42, Academic Press, New York, pp. 787-804, 2008.

BOOKS:

1. Farrell PM (Ed.). Lung Development: Biological and Clinical Perspectives, Academic Press, New York, 1982. Volume I. Biochemistry and Physiology and Volume II. Neonatal Respiratory Distress.
2. Farrell PM, Taussig LM. Bronchopulmonary dysplasia and related chronic respiratory disorders. Report of the Ninetieth Ross Conference on Pediatric Research. Columbus, OH: Ross Laboratories, 1986.
3. Rudolph AM (Ed.), Farrell PM (Assoc. Ed.). Essentials of Clinical Nutrition in Pediatrics, 19th Edition, Appleton and Lange, pp. 211-263, 1991.

INVITED EDITORIALS/COMMENTARIES:

1. Perelman R, Farrell PM. The impact of perinatal intensive care and regionalization in Wisconsin. *Wis Med J*. 77:S35-S36, 1978.
2. Farrell PM. Early diagnosis of cystic fibrosis: to screen or not to screen - an important question. *Pediatrics*, 73:115-117, 1984.
3. Farrell PM. Nutrition in cystic fibrosis. *Bol Asoc Med P R*. 76:352-4, 1984.
4. Farrell PM. Preparing new physicians for the next millennium. *Wisc Med J* 97:17-20, 1998.
5. Farrell PM. Early diagnosis of cystic fibrosis can improve children's growth. *BMJ* 317:1017, 1998.
6. Farrell, PM. Creating much more than a medical school. *Wisc Med J* 98:59-60, 1999.
7. Dunn MJ and Farrell. Medical Schools Spearhead Assessment of Wisconsin's Health Needs. *Wisc Med J* 99:11, 2000.
8. Kindig DA and Farrell PM. Assessing Wisconsin's health needs and priorities. *Wisc Med J* 99:25-26, 2000.
9. Farrell PM. Integrated health sciences learning: a dream becomes reality. *Wisc Med J*. 99:79-81, 2000.
10. Grosse SD, Khoury MJ, Hannon WH, Boyle CA, Farrell PM. Early diagnosis of cystic fibrosis. *Pediatrics*. 107:1492, 2001.
11. Farrell PM, Fiore M. Solving complex health problems with interdisciplinary approaches. *Wisc Med J*. 100:75-6, 2001.
12. Farrell PM, Hammes B. A promise for palliative care at the end-of-life. *Wisc Med J*. 100:59-66, 2001.
13. Farrell PM, Mejicano G. Preparing for bioterrorism. *Wisc Med J*. 101:35-6, 2002.
14. Farrell PM. Enhancing men's urologic health. *Wisc Med J*. 101:46-7, 2002.
15. Turkal NW, Farrell P, Howe GE. A view from the clinical campus: a partnership of an academic medical center with an integrated delivery system. *Wisc Med J*. 102:19-23, 2003.

RESEARCH GRANTS as PI, unless otherwise noted; (agency and total direct costs award):

1973-1975	Cystic Fibrosis Foundation (\$49,050): "Effects of Vitamin E Deficiency in Man"
1977-1979	Cystic Fibrosis Foundation (\$57,960): "Essential Fatty Acids in Cystic Fibrosis As Related to Vitamin E Deficiency"
1977-1980	National Foundation-March of Dimes (\$62,330): "Substrate-Mediated Control of Lung Phosphatidylcholine Metabolism"
1978-1981	National Institutes of Health (HD 11429-01) (\$224,248): "Fetal Lung Development in the Diabetic Pregnancy"
1977-1981	Cystic Fibrosis Foundation (\$46,369): "Care, Teaching, and Research Center Grant"
1979-1981	Juvenile Diabetes Foundation (\$73,749): "Mechanisms of abnormal Fetal and Neonatal Lung Metabolism in Pregnancies Complicated by Diabetes" (with Dr. Michael J. Engle)
1979	Organon Pharmaceuticals, Inc. (\$20,000): "Assessment of Digestants in Cystic Fibrosis"
1979-1982	Cystic Fibrosis Foundation (\$59,141): "Correction of Linoleic Acid Deficiency in Cystic Fibrosis" (with Dr. Elaine H. Mischler)
1981-1986	National Institutes of Health (1P50 HL27358) (\$2,784,390): "SCOR: Nutrition and Metabolism in Infant Lung Disease"
1982-1985	American Lung Association (\$48,000): "Pediatric Pulmonary Fellowships-Institutional Training Grant"
1984	Mead Johnson, Inc. (\$3,500): "Choline Nutrition in Low Birthweight Infants"
1984-1989	Cystic Fibrosis Foundation (A001 5-01) (\$869,660): "Benefits and Risks of Cystic Fibrosis Neonatal Screening" (Voluntarily terminated in 1985)
1985-1987	Mead Johnson Nutritional Group (\$18,000): "Nutritional Benefits of Cystic Fibrosis Screening"
1985-1990	National Institutes of Health (1R01 AM34108)(\$1,056,082): "Pulmonary Benefits of Cystic Fibrosis Neonatal Screening"
1987-1988	National Institutes of Health (IROI HL 38149) (\$783,513): "Risk Factors in Bronchopulmonary Dysplasia" (Co-Principal Investigator with Dr. Mari Palta)
1988-1990	Cystic Fibrosis Foundation (\$263,973): "Supplement of Assessment of the Benefits and Risks of Neonatal Screening for Cystic Fibrosis"
1988-1991	Mead John Nutritionals (\$18,150): "Cystic Fibrosis Neonatal Screening"
1991-1995	National Institutes of Health (2ROI DK 34108) (\$1,312,749): "Pulmonary Benefits of Cystic Fibrosis Neonatal Screening"
1991-1996	National Institutes of Health (1P50 HL 46478) (\$2,628,944) "SCOR: Lung Biology and Diseases in Infants and Children - Pathology of Bronchopulmonary Dysplasia"

1994-1999	National Institutes of Health (2 MO1 RR03186) (\$12,036,474): "General Clinical Research Center - University of Wisconsin"
1995-1998	National Institutes of Health (2ROI DK 34108) (\$874,478): "Pulmonary Benefits of Cystic Fibrosis Neonatal Screening"
1996-2000	Howard Hughes Medical Institute; (\$2,800,000): "UW/HHMI Carrier Development Program in Molecular Mechanisms of Disease"
1996-2001	The Robert Wood Johnson Foundation (\$349,508): "Health Professions Partnership Initiative"
1998-2001	National Institutes of Health (2RO1 DK 34108) (\$1,027,212): "Pulmonary Benefits of Cystic Fibrosis Neonatal Screening"
1999-2004	National Institutes of Health (2 MO1 RR03186)(\$15,839,890): "General Clinical Research Center - University of Wisconsin"
2000-2003	Howard Hughes Medical Institute; (\$1,600,000) "UW/HHMI Carrier Development Program in Molecular Mechanisms of Disease"
2001-2006	National Institutes of Health (2RO1 DK 34108) (\$2,472,753): "Pulmonary Benefits of Cystic Fibrosis Neonatal Screening"
2003-2008	National Institutes of Health (K01 HL072530) (\$584,125): "Quality of Communication after Newborn Genetic Screening" (Advisor to PI, Dr. Michael Farrell)
2006-2011	Cystic Fibrosis Foundation (FARREL06A0) (\$787,644): "Pulmonary Benefits of Cystic Fibrosis Neonatal Screening: Psychosocial Outcomes"
2006-2011	National Institutes of Health (5R01 DK072126) (\$185,000): "Malnutrition and Lung Disease in Cystic Fibrosis" (Co-investigator with PI, Dr. HuiChuan Lai)
2007-2008	Worldwide Universities Network (\$8,000): "The Ancient Origin of Cystic Fibrosis"
2007-2012	National Institutes of Health (2RO1 DK 34108) (\$1,968,982): "Pulmonary Benefits of Cystic Fibrosis Neonatal Screening"
2008-2011	National Institutes of Health (R21 HG004252) (\$356,913): "Developing a Family-Centered Approach for Genetic Counseling: A New Paradigm" (Co-Investigator)
2008-2011	National Institutes of Health (R01 HL086691) (\$1,051,250): "Improvement of Communication Process and Outcomes after Newborn Genetic Screening" (Advisor to PI, Dr. Michael Farrell)
2009-2011	National Institutes of Health (1RC1HL100819) (\$499,940): "A Rapid-Throughput Feedback Intervention for Population-Scale Communication Quality Assurance Projects" (Subcontract PI with PI, Dr. Michael Farrell)
2010-2012	National Institutes of Health (1R21HL102523): IL-1 Family Gene Polymorphisms and Susceptibility to P. aeruginosa in CF Patients (Co-Investigator)